| Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis (NCT07695701) | Eidos Therapeutics, a BridgeBio company | 2026-07-01 |
| Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants (NCT04988386) | Eidos Therapeutics, a BridgeBio company | 2021-10-27 |
| Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) (NCT04882735) | Eidos Therapeutics, a BridgeBio company | 2021-09-08 |
| A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects (NCT04769479) | Eidos Therapeutics, a BridgeBio company | 2021-03-28 |
| Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy (NCT04418024) | Eidos Therapeutics, a BridgeBio company | 2020-10-21 |
| Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (NCT03860935) | Eidos Therapeutics, a BridgeBio company | 2019-03-19 |
| Open-Label Study of AG10 in Patients with Cardiomyopathy (NCT03536767) | Eidos Therapeutics, a BridgeBio company | 2018-08-08 |
| Study of AG10 in Amyloid Cardiomyopathy (NCT03458130) | Eidos Therapeutics, a BridgeBio company | 2018-04-27 |
| Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 (NCT03294707) | Eidos Therapeutics, a BridgeBio company | 2017-09-11 |